Individuals living with HIV have been underrepresented in operational research and trials of shortened all-oral regimens for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). This prospective observational cohort study reports safety and effectiveness outcomes for a nine-month, all-oral MDR/RR-TB regimen implemented in Lesotho, a high HIV-prevalence setting.
The analysis included patients who initiated the nine-month regimen between 2020 and 2023. The study prospectively followed participants to characterize safety and treatment effectiveness both overall and stratified by HIV status. Safety was assessed by summarizing the frequency and timing of clinically relevant adverse events. Effectiveness was described at the end of treatment and as sustained treatment success eighteen months after treatment initiation. The study design was observational and operational in nature; additional design details beyond those reported were not provided in the source.
A total of 255 patients who started the shortened all-oral regimen were included in the analysis. Of these, 161 (63.1%) were living with HIV. The regimen combined bedaquiline, linezolid, a fluoroquinolone, delamanid, and clofazimine. The source did not report additional regimen dosing specifics, duration of each component beyond the nine-month total, or the specific fluoroquinolone used.
Safety evaluation summarized clinically relevant adverse events by frequency and timing. Across the cohort and irrespective of HIV status, the most frequently observed clinically relevant adverse event was peripheral neuropathy, followed by myelosuppression. The report indicates adverse events were common but describes them as manageable and not apparently substantially detrimental to overall treatment outcomes. The source did not provide detailed event rates by grade, management strategies, or timing for each adverse event class beyond noting frequency and order of common events.
Effectiveness endpoints included treatment outcome at the end of the nine-month regimen and sustained success measured eighteen months after treatment initiation. The study reports unadjusted estimated rates of sustained treatment success with accompanying 95% confidence intervals. These estimates reflect the operational effectiveness of the regimen in routine programmatic conditions.
Overall, the estimated unadjusted rate of sustained treatment success at 18 months post-treatment initiation was 86.4% (95% confidence interval [CI]: 81.4%, 90.5%). When stratified by HIV status, the estimated unadjusted sustained success was 85.0% (95% CI: 78.2%, 90.4%) among patients living with HIV and 88.8% (95% CI: 80.3%, 94.5%) among people without HIV. These results indicate similar effectiveness of the nine-month regimen regardless of HIV status within this cohort. The source did not provide adjusted analyses controlling for potential confounders, nor did it provide subgroup breakdowns beyond HIV status in the text provided.
The authors conclude that the nine-month all-oral regimen combining bedaquiline, linezolid, a fluoroquinolone, delamanid, and clofazimine achieved excellent effectiveness in this Lesotho cohort. Although clinically relevant adverse events were common—most notably peripheral neuropathy and myelosuppression—they were described as manageable and did not appear to substantially impact final treatment success. Outcomes were comparable by HIV status, supporting use of this shortened all-oral regimen in populations with a high prevalence of HIV.
The study received ethical approval from the Lesotho Ministry of Health National Ethics Committee and the Harvard Longwood Campus Institutional Review Board. All participants provided written informed consent. The authors declared no competing interests. Funding was reported from the National Institutes of Health (R01AI46095). The source noted that all data produced are available on reasonable request to the authors. No additional regulatory or trial registration identifiers were reported in the summarized source text beyond the authors’ statement that relevant registrations and reporting guidelines were followed.
In a prospective observational cohort of 255 patients in Lesotho, including 63.1% living with HIV, a nine-month all-oral regimen containing bedaquiline, linezolid, a fluoroquinolone, delamanid, and clofazimine produced an estimated 86.4% unadjusted sustained treatment success at 18 months. The most common clinically relevant adverse events were peripheral neuropathy and myelosuppression. Results were similar by HIV status, and adverse events were described as manageable. Ethical approvals and NIH funding were reported.